Anavex Life Sciences Corp (AVXL)

[OFP]

We don’t know of anything in the near term that needs $250m, not sure how you figure o/s needs to be extended by 100m?

A3-71 is going to cost a bit taking into P1, call it $20m.

On the pessimistic side this can be used as a company reboot (dilution to penny status, reverse splits, etc) for A3-71 if/when 2-73 trials fail.

On optimistic side it could be used to pretend they might market 2-73 themselves and therefore apply some pressure (non-credible IMO) on potential partners should they show evidence of efficacy.

My bet (if I make one) will be on the former but it pretty much means Missling can do whatever he wants for the next decade or so regardless of outcome with little interference from investors.